Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval
1. Eli Lilly's orforglipron pill met key trial endpoints for weight loss. 2. Patients lost an average of 22.9 pounds over 72 weeks. 3. Approval application for orforglipron is anticipated imminently. 4. Adverse effects like nausea and vomiting were reported in high numbers. 5. LLY shares increased over 4% after the trial results.